50
total announcements
DRREDDY.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 15 Oct 2026
Market Cap
₹1.01 L Cr
P/E (TTM)
30.6
P/E (Forward)
20.7
EPS (TTM)
₹39.74
52W Low
₹1,101.00
52W High
₹1,414.90
Dividend Yield
0.65%
Beta
0.25
Price / Book
2.6
Return on Equity
8.84%
Debt / Equity
18.6
Revenue (TTM)
₹33,119 Cr
Gross Margin
50.18%
Operating Margin
4.25%
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has informed the Exchange that the USFDA completed a Pre-Approval Inspection (PAI) at its FTO-9 manufacturing facility in Visakhapatnam, Andhra Pradesh, with three observations, which the company will address within the stipulated timeline.
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has informed the Exchange about a completed Pre-Approval Inspection (PAI) at its FTO-11 manufacturing facility in Pydibhimavaram, Andhra Pradesh by the United States Food and Drug Administration (USFDA), with two observations issued in a Form 483.
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has announced the release of Q2FY27 results on October 23rd, 2026, along with an earnings call at 19:30 PM IST / 10:00 AM ET.
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the securities have been listed on the stock exchange and the security certificates received for dematerialisation have been verified and cancelled.
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has informed the Exchange about imposition of a penalty of $32,350.20 to its step-down wholly owned subsidiary, Dr. Reddy's Laboratories, Inc., due to misclassification of Fiscal year reference at the time of tax payment.
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, and has announced a Board meeting on October 23, 2026, to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter ending on September 30, 2026.
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has informed the Exchange about Schedule of meet for an investor conference with Nomura on September 25, 2026, in Hyderabad.
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has entered into an exclusive distribution and marketing agreement with Takeda Biopharmaceuticals India Private Limited for Qdenga, a dengue vaccine, in the private market in India.
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has clarified a news article regarding a voluntary license for Gilead's once-yearly HIV prevention drug, stating that the news is correct and the company has made a press release on the matter.
Dr. Reddy's Laboratories Limited
The Bombay Stock Exchange (BSE) has sought clarification from Dr. Reddy's Laboratories Limited regarding a recent news article about the company obtaining a voluntary license for Gilead's once-yearly HIV prevention drug. The company's response is pending.
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has informed the Exchange about a notice to shareholders regarding loss of share certificates and a special window for transfer and dematerialisation of physical shares.
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has informed the Exchange about a USFDA records assessment at its API manufacturing facility in Mexico, with two observations issued and a response timeline stipulated.
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has informed the Exchange about the allotment of 375 equity shares to eligible employees under the Dr. Reddy's Employees ADR Stock Options Scheme, 2007.
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has informed the Exchange about the schedule of meet with ICICI Securities and Bank of America, to be held on September 17 and 24, 2026, respectively.
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has informed the Exchange about the allotment of 4,110 equity shares to eligible employees pursuant to the exercise of their Stock Options under Dr. Reddy's Employees Stock Options Scheme, 2002.
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has informed the Exchange about a copy of newspaper publication regarding loss of share certificates, while Nectar Lifesciences Limited has informed the Exchange about a notice to shareholders regarding the 31st Annual General Meeting (AGM) and other information.
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has informed the Exchange that the USFDA completed a GMP inspection at its formulations manufacturing facility in Bachupally, Hyderabad, and issued a Form 483 with four observations, which the company will address within the stipulated timeline.
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has informed the Exchange about a General Update regarding a USFDA inspection outcome at their API manufacturing facility in Mirfield, West Yorkshire, United Kingdom. The inspection outcome was classified as 'Voluntary Action Indicated (VAI)' and concluded that the inspection is officially closed under 21 CFR 20.64(d)(3).
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has informed the Exchange about the resignation of a Director/KMP/SMP.
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has informed the Exchange about change in Management, with Mr. Deepak Sapra resigning as CEO, API and Services and Senior Management Personnel, effective from November 12, 2026.